How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Treatment Resistant Depression Drug Market
- By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Atypical Antipsychotics, NMDA Receptor Antagonists, Tricyclic Antidepressants (TCAs)
- By Route of Administration: Oral, Intravenous, Intranasal, Transdermal
- By Mechanism of Action: Glutamatergic Modulators, Monoamine Reuptake Inhibitors, GABAergic Agents, Neurostimulation Adjuncts
- By Patient Population: Adult, Geriatric, Adolescent
- By Treatment Setting: Inpatient, Outpatient, Day Hospital
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Selective Serotonin Reuptake Inhibitors (SSRIs) leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Treatment Resistant Depression Drug Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →H. Lundbeck A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Otsuka Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Axsome Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sage Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Alkermes plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Relmada Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Jazz Pharmaceuticals plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Roche Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Takeda Pharmaceutical Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sunovion Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Neurocrine Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Selective Serotonin Reuptake Inhibitors (SSRIs)42.7
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)17.3
- Atypical Antipsychotics10.3
- NMDA Receptor Antagonists15.1
- Tricyclic Antidepressants (TCAs)14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson11.3
- H. Lundbeck A/S18.3
- Otsuka Pharmaceutical Co. Ltd.9.8
- Axsome Therapeutics Inc.9.4
- Sage Therapeutics Inc.10.7
- Alkermes plc12.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe25.9
- Asia Pacific19.9
- Latin America13.3
- Middle East and Africa10.0
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 83 | 74 | 94 | 85 | 76 | 91 | 84 |
| H. Lundbeck A/S | 80 | 73 | 78 | 91 | 86 | 90 | 83 |
| Otsuka Pharmaceutical Co. Ltd. | 72 | 78 | 70 | 83 | 70 | 79 | 75 |
| Axsome Therapeutics Inc. | 80 | 78 | 81 | 69 | 63 | 71 | 74 |
| Sage Therapeutics Inc. | 55 | 77 | 68 | 65 | 57 | 75 | 66 |
| Alkermes plc | 57 | 49 | 57 | 50 | 53 | 71 | 56 |
| Relmada Therapeutics Inc. | 56 | 48 | 52 | 59 | 53 | 59 | 55 |
| Jazz Pharmaceuticals plc | 56 | 59 | 49 | 58 | 49 | 50 | 54 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- H. Lundbeck A/S
- Otsuka Pharmaceutical Co. Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| H. Lundbeck A/S | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Otsuka Pharmaceutical Co. Ltd. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Axsome Therapeutics Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Sage Therapeutics Inc. | − | ◐ | ◐ | ✓ | ◐ | ◐ |
| Alkermes plc | − | − | − | − | ◐ | ◐ |
| Relmada Therapeutics Inc. | ◐ | − | ◐ | − | ◐ | ◐ |
| Jazz Pharmaceuticals plc | ◐ | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Drug Class in North America, then scale across Treatment Resistant Depression Drug Market — a $324M beachhead inside a $6.54B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Selective Serotonin Reuptake Inhibitors (SSRIs)
Best fit — highest urgency & budget in Drug Class.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Strong fit — clear ROI and a fast path to value.
Atypical Antipsychotics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Treatment Resistant Depression Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Treatment Resistant Depression Drug Market is a resilient opportunity — $1.41B by 2033, compounding at 3.5%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.5% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Treatment Resistant Depression Drug Market — a $1.20B market by 2033. Plan: grow share from 8.1% to 16.3%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 16.3% | Behind |
| Revenue | $93M | $196M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 32.2% | 40.3% | Ahead |
| Customer retention | 91.0% | 96.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Treatment Resistant Depression Drug Market conversation — a $6.15B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Treatment Resistant Depression Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Treatment Resistant Depression Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Treatment Trolley Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportTree Care Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportTree Care Service Market
Market size, share, segmentation and regional forecast.
$713M market · 2025 base year
View reportTree Grate Cover Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportTree Molasses Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportTree Shakers Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportTree Trimming Service Market
Market size, share, segmentation and regional forecast.
$940M market · 2025 base year
View reportTreeless Saddles Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportTrekking Pole Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportTrekking Poles (Poles) Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTrekking Umbrella Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportTrellis Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy